Janux Therapeutics

We are so proud of #TeamJanux, and we appreciate all the hard work you do #EveryDayatJanux in our mission to create new medicines that improve how cancer is treated. For Employee Appreciation Week, we shared with each other how each of us makes an impact, not only for our team, but also in the lives of patients. Together, we are making a difference! 

For Fabrece Roup, collaboration isn't a buzzword. It's an integral part of his job as a researcher. Hear why this particular value speaks to him, and how the diverse sets of skills, knowledge, and creativity at Janux inspire and motivate him to achieve more each day to address the unmet needs of cancer patients. #Culture #CoreValues #science #LifeAtJanux #collaboration #oncology #cancer

Today we reported our first quarter (Q1) financial results and business highlights. Enrollment is ongoing for PSMA-TRACTr (JANX007) in prostate cancer and for EGFR-TRACTr (JANX008) in solid tumors. JANX007 data and doses selected for expansion cohorts is anticipated in 2H 2024.   Read the press release for more: https://lnkd.in/gV796Htw    #Q1Earnings #ProstateCancer #cancer #TRACTr #TRACIr #TCellEngagers

For National Cancer Research Month, we want to say thank you to our team and the researchers, clinicians, and patients who are taking part in clinical trials to advance new therapeutics. We've made important progress, but there is still much to be done. Together, we can push forward and make a difference in the lives of those affected by #cancer. Learn more about our #clinicaltrials and the contributions Janux is making to #cancerresearch: https://lnkd.in/ggvVSxn3 #NCRM24 #CancerResearchSavesLives #TCellEngagers #cancer #oncology #immunotherapy #immunomodulators

Thank you Padres Pedal the Cause and #TeamJanux for a great #padrespedal24! Together, we're proud to support #padrespedalthecause, and we dedicate each day to making a difference in the fight against #cancer. #GoJanux

We're gearing up to give our all for #cancer research. The Janux team has been hitting the pavement, the gym, and the trails to prepare for this weekend's Padres Pedal the Cause. Learn more and support the cause at: https://lnkd.in/gu3qsS7G #padrespedal24 #SanDiego

Janux CEO David Campbell was featured on BiotechTV to discuss the most recent data in ongoing dose escalation trials for PSMAxCD3-TRACTr JANX007 in mCRPC and EGFRxCD3-TRACTr JANX008 in solid tumors. Watch the interview here: https://lnkd.in/gWrbm_Aj    Read the press release for more info: https://lnkd.in/g8EzNwM7    #ProstateCancer #TRACTr #TRACIr #TCellEngagers #cancer

From an early age, Sara Walsh was taught to behave honorably, even when no one is watching. That core value, instilled in Sara by her father, is one we share here at Janux. She recently reflected on how integrity has shaped her life and career as an executive administrative assistant. Thanks for sharing your insights, Sara, and for exemplifying integrity in all you do! #Culture #LeadByExample #CoreValues #LifeatJanux #integrity

Today we announced our Q4 and full year 2023 financial results and business highlights. These include recently presented positive Phase 1 clinical trial data for PSMA-TRACTr JANX007 in mCRPC and for EGFR-TRACTr JANX008 in solid tumors. With a further strengthened financial foundation from our recent offering, we're well-positioned to advance our innovative cancer #immunotherapies.   Read the press release for more: https://lnkd.in/g-sqW6pa   #Q4Earnings #ProstateCancer #TRACTr #TRACIr #TCellEngagers

We are pleased to announce encouraging safety and efficacy data in ongoing dose escalation trials for PSMAxCD3-TRACTr JANX007 in #mCRPC and EGFRxCD3-TRACTr JANX008 in solid tumors. Join our virtual investor event today at 4:30pm ET. Read the release for more details: https://lnkd.in/g8EzNwM7 #TCellEngagers #cancer #oncology #immunotherapy #immunomodulator #immunooncology #clinicaltrial #mCRPC #prostatecancer